Irritable bowel syndrome (IBS) can significantly affect everyday life. Abdominal pain, bloating, diarrhea, constipation, and unpredictable bowel habits often make finding an effective approach to digestive support particularly challenging.
For years, probiotics have been investigated as one possible approach. However, their effects vary considerably depending on the strain, formulation, and individual characteristics.
Recent clinical research suggests that selected postbiotics may offer another promising option.
Why Are Postbiotics Being Investigated for IBS?
IBS is a disorder of gut–brain interaction. Its symptoms may involve multiple factors, including altered intestinal sensitivity, bowel motility, microbial activity, and communication between the digestive and nervous systems.
Postbiotics contain inactivated microorganisms and/or their components that provide a health benefit. Their biological activity does not require the administered bacteria to remain alive or multiply.
This creates an interesting opportunity to support digestive health without introducing additional viable bacterial cultures.
A 2026 Meta-Analysis: 1,062 Participants
On May 8, 2026, the Journal of Gastroenterology and Hepatology published a systematic review and meta-analysis examining postbiotics in adults with IBS.
The international research team included specialists from Universiti Sains Malaysia, Southern Medical University in China, Tanta University and Ain Shams University in Egypt, and other academic institutions.
The analysis combined four randomized controlled trials involving 1,062 participants.
Compared with placebo, postbiotic interventions demonstrated several encouraging outcomes:
- Reduced overall IBS symptom severity.
- A 2.46-fold greater likelihood of achieving at least a 30% reduction in abdominal pain.
- Improved quality of life with oral capsule formulations.
- No statistically significant difference in reported treatment-emergent adverse events.
The studies differed in their formulations and methods, and the overall certainty of evidence was rated low. Nevertheless, the findings provide a strong rationale for further clinical investigation.
Postbiotics and Digestive Discomfort
One particularly relevant clinical trial compared live and heat-treated forms of Bifidobacterium longum CECT 7347, also known as ES1.
The study, published in Gut Microbes in April 2024, involved 200 adults with diarrhea-predominant IBS and lasted 12 weeks.
Both forms produced clinically meaningful improvements compared with placebo, demonstrating that selected bacterial preparations can retain beneficial activity after heat treatment.
Importantly, these findings relate specifically to IBS characterized predominantly by diarrhea and should not automatically be extended to constipation-predominant IBS.
Can Postbiotics Help People Who Do Not Tolerate Probiotics?
Some people experience gas, bloating, or digestive discomfort when taking live probiotic products.
Inactivated microorganisms do not actively ferment intestinal substrates or reproduce after administration. This technological difference makes postbiotics particularly interesting for individuals with sensitive digestive systems.
However, tolerability and effectiveness depend on the individual preparation, rather than simply whether the bacteria are alive or inactive.
Read more: Why Do Probiotics Cause Bloating and Gas?
NBH Postbiotic Pro: A Multicomponent Approach
Research into digestive comfort, microbiome composition, intestinal barrier function, and immune regulation helped shape the development of NBH Postbiotic Pro.
The formula combines three selected postbiotic components:
- ES1 — heat-treated Bifidobacterium longum.
- beLP1 — inactivated Lactiplantibacillus plantarum.
- pAkk11 — pasteurized Akkermansia muciniphila.
Each component represents a complementary direction in gut health research.
The objective is to provide multidimensional digestive support, with particular attention to individuals with sensitive gastrointestinal systems.
Research on individual components supports the scientific rationale behind this approach, although the finished combination has not yet been clinically evaluated for IBS.
Conclusion
Clinical research suggests that selected postbiotics may become valuable tools for supporting digestive comfort and managing certain gastrointestinal symptoms associated with IBS.
The development of standardized, multicomponent postbiotic preparations represents a promising direction in modern microbiome science.
Further research will help establish which formulations are most effective for different types of digestive disorders.
Related Articles
- Postbiotics for Gut Health: What Clinical Studies Reveal
- Postbiotics vs. Probiotics: Why Postbiotics Are the Next Generation
Scientific References
- Ayad ME et al. Efficacy and Safety of Postbiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Journal of Gastroenterology and Hepatology. 2026;41(7):1994–2005. https://doi.org/10.1111/jgh.70421
- Srivastava S et al. Randomized controlled trial of live and heat-treated Bifidobacterium longum CECT 7347 in diarrhea-predominant irritable bowel syndrome. Gut Microbes. 2024;16(1):2338322. https://doi.org/10.1080/19490976.2024.2338322
- Salminen S et al. ISAPP consensus statement on the definition and scope of postbiotics. Nature Reviews Gastroenterology & Hepatology. 2021. https://doi.org/10.1038/s41575-021-00440-6
Leave a Reply